The company is preparing for Phase 3 trials of paltusotine for carcinoid syndrome and atumelnant for CAH. Additionally, Crinetics ended 2024 with $1.4 billion in cash reserves, which is expected to fund operations into 2029. In earnings-related news, Kinetics Pharmaceuticals, which shares similarities with Crinetics, reported a significant revenue drop for 2024, down to $1 million from $4 million in 2023, alongside increased research and development expenses. Despite these financial challenges, Kinetics is preparing for the potential launch of its new treatment for acromegaly, paltucitine, and expanding its commercial infrastructure in the U.S. and Europe. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.